Purchase this article with an account.
flore DE BATS, Jean Daniel Grange, Philippe Denis, Laurent Kodjikian; Intravitreal Injection Of Bevacizumab For Naive Myopic Choroidal Neovascularization: Results Obtained After 18 Months Of Treatment. Invest. Ophthalmol. Vis. Sci. 2012;53(14):2948.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Choroidal neovascularization is a complication of high myopia which can reduce the visual prognosis in young patients. The purpose of this study was to evaluate the efficacity and safety of bevacizumab in the first-line treatment of myopic choroidal neovascularization.
We report a retrospective study of patients with subfoveal or juxtafoveal choroidal neovascularization associated with pathologic myopia treated with intravitreal injection of bevacizumab in Lyon, France, from January 2009 to June 2010. Best-corrected visual acuity, ocular pressure, fundus examination, optical coherence tomography and fluorescein angiography were performed for each patient at baseline and monthly. Indications for retreatment were persistent on recurrence of exsudative activity.
The study included 7 eyes of 7 patients with a mean of age of 44 and spherical equivalent refractive error of -12 diopters. The mean follow-up time was 18 months. The mean number of intravitreal injections was 3 at the end of the first year. 6 patients maintained or improved their vision. No injection complications or drug-related side effects were noted during the follow-up period.
In this study, intravitreal injection of bevacizumab seems to be a safe and effective treatment for myopic choroidal neovascularization resulting in functionnal and anatomic improvement.
This PDF is available to Subscribers Only